title: Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis.
authors.forename: Adriana M W
authors.initials: AM
authors.lastname: van Marion
authors.forename: Johannes J A
authors.initials: JJ
authors.lastname: Auwerda
authors.forename: Monique C
authors.initials: MC
authors.lastname: Minnema
authors.forename: Rolinda
authors.initials: R
authors.lastname: van Oosterom
authors.forename: Jelle
authors.initials: J
authors.lastname: Adelmeijer
authors.forename: Philip G
authors.initials: PG
authors.lastname: de Groot
authors.forename: Frank W G
authors.initials: FW
authors.lastname: Leebeek
authors.forename: Pieter
authors.initials: P
authors.lastname: Sonneveld
authors.forename: Henk M
authors.initials: HM
authors.lastname: Lokhorst
authors.forename: Ton
authors.initials: T
authors.lastname: Lisman
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001780:Blood Coagulation Tests; D004359:Drug Therapy, Combination; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D009101:Multiple Myeloma / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D011446:Prospective Studies; D012307:Risk Factors; D013792:Thalidomide / Q000008:administration & dosage; D013923:Thromboembolism / Q000209:etiology*; D020246:Venous Thrombosis / Q000209:etiology*
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D013792:Thalidomide